Maximilian Merz1, Dorde Komljenovic1, Wolfhard Semmler1, Tobias Buerle1
1Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany, Germany
Imaging treatment response of bone metastases is pivotal for clinical practice. The most recent version of the response evaluation criteria in solid tumors (RECIST) recommends measuring the osteolytic bone lesion by CT and the respective soft tissue tumor by MRI. However, changes in morphology and lesion size are usually observed months after the initiation of treatment. In our study we report that non-invasive imaging of tumor cellularity by DWI as well as tumor vasculature by DCE-MRI and VSI serves as an early quantifiable biomarker for the assessment of treatment response to an anti-angiogenic therapy in experimental breast cancer bone metastases.